<DOC>
	<DOCNO>NCT00021073</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine flavopiridol , fluorouracil , leucovorin without irinotecan treating patient advance cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose flavopiridol , fluorouracil , leucovorin calcium without irinotecan patient advanced malignancy . II . Assess toxic effect regimens patient . III . Determine clinical response patient treat regimen . OUTLINE : This dose-escalation study flavopiridol ( FLAVO ) , fluorouracil ( 5-FU ) , irinotecan . Patients assign 1 2 group . Groups I II conduct sequentially . Group I : Patients receive FLAVO IV 24 hour day 1 leucovorin calcium ( CF ) IV 5-FU IV 1.5 hour daily day 2-5 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos FLAVO 5-FU maximum tolerate dos ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Group II : Once MTDs FLAVO 5-FU determine , patient receive FLAVO , CF , 5-FU group I plus irinotecan IV 1.5 hour day 1 . Courses repeat group I . Cohorts 3-6 patient receive escalate dos irinotecan MTD determine . The MTD define group I . Patients follow 3 month . PROJECTED ACCRUAL : A maximum 57-90 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Histologically confirm malignancy Unresectable tumor No known standard therapy curative potential capability extend life expectancy No untreated CNS metastasis Performance status ECOG 02 At least 12 week Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8 g/dL Direct bilirubin great upper limit normal ( ULN ) AST great 3 time ULN ( 5 time ULN liver metastasis present ) Creatinine great 1.5 time ULN No New York Heart Association class III IV heart disease No seizure disorder No uncontrolled infection No baseline diarrhea , define least 4 loose liquid stools/day Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception More 4 week since prior biologic therapy More 4 week since prior immunotherapy No concurrent immunotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) fully recover acute reversible effect No concurrent chemotherapy More 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy No concurrent ancillary investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>